Altimmune Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, auditor ratification, executive compensation, and amendments to share authorization and employee stock plans. All proposals passed by majority or plurality vote, with results to be filed with the SEC.
-
Phase II data for pemvidutide in MASH showed strong resolution and anti-fibrotic effects, supporting a differentiated phase III design with AI-assisted histology. Progress continues in AUD and ALD trials, with financial and leadership enhancements positioning for late-stage success.
-
Recent clinical data and regulatory milestones support advancing pemvidutide into phase III for MASH, with a focus on its unique dual agonism, strong tolerability, and potential for both monotherapy and combination use. Ongoing phase II trials in AUD and ALD may further expand its indications.
-
Pemvidutide is advancing toward a phase III trial in MASH, supported by strong phase II data on MASH resolution, weight loss, and tolerability. Its unique one-to-one glucagon/GLP-1 ratio and commercial strategy aim to address key unmet needs, with a solid financial runway into 2028.
Fiscal Year 2025
-
Pemvidutide advanced toward phase 3 for MASH with strong phase 2b efficacy, FDA Breakthrough Therapy designation, and robust financials supporting a global pivotal trial. Physician interest is high, and cash runway extends into 2028.
-
IMPACT phase 2b 48-week data for pemvidutide in MASH showed significant, dose-dependent improvements in fibrosis markers, liver fat, and weight loss, with a strong safety and tolerability profile. Regulatory alignment with the FDA supports a phase 3 program using both 1.8 mg and 2.4 mg doses and innovative AI pathology tools.
-
Leadership transition is underway as the company prepares for phase III trials and commercialization, with key regulatory and data milestones expected by year-end. Pemvidutide’s flexible trial design and strong early data support its potential in MASH, AUD, and ALD, while commercial capabilities are being built.
-
A dual GLP-1/glucagon agonist is advancing for MASH, AUD, and ALD, showing strong efficacy and tolerability in early trials. Phase three planning is underway, with flexibility for regulatory changes and a focus on both liver and metabolic benefits.
-
Pemvidutide, a balanced glucagon/GLP-1 dual agonist, demonstrated rapid MASH resolution, strong anti-fibrotic activity, and quality weight loss in 24-week data, with 48-week results expected soon. The program is well-positioned for regulatory flexibility and expansion into AUD and ALD, supported by strong tolerability and financial resources.
-
Pemvidutide showed strong anti-fibrotic and weight loss effects in MASH, with robust financials and flexible phase three planning. Rapid trial enrollment and positive market feedback highlight significant commercial potential across MASH, AUD, and ALD.
-
The conference highlighted pemvidutide’s strong phase IIb results in MASH, with robust efficacy, best-in-class tolerability, and a unique dual mechanism. Flexible trial design and upcoming regulatory milestones position it well for phase III and commercial success.
-
Phase II data showed rapid, robust MASH resolution, weight loss, and strong tolerability, with AI and NITs supporting efficacy. The phase III trial is designed for regulatory flexibility, and the drug’s dual-action profile positions it strongly in a growing MASH market.
-
The meeting covered director elections, auditor ratification, executive compensation, and governance matters. All proposals passed by majority or plurality vote, and no shareholder questions were submitted.
-
Pemvidutide, a dual GLP-1/glucagon agonist, is showing class-leading efficacy and tolerability in NASH, with robust weight loss and anti-inflammatory effects. Regulatory strategy leverages non-invasive endpoints, and the drug is being advanced for NASH, obesity, AUD, and ALD, with key data and FDA meetings expected in Q4.
-
Pemvidutide, a dual GLP-1/glucagon agonist, demonstrated class-leading MASH resolution and rapid liver fat reduction at 24 weeks, with strong non-invasive test results and high physician interest. Regulatory acceptance of computer-based reads and NITs is advancing.
-
Pemvidutide achieved significant efficacy and safety in MASH at 24 weeks, with strong financials and a strategic shift toward phase III and commercialization. Full 48-week data and key FDA meetings are expected in Q4, with ongoing trials in AUD and ALD.
-
Pemvidutide achieved up to 59.1% MASH resolution at 24 weeks with significant weight loss and a strong safety profile. AI and non-invasive tests showed promising anti-fibrotic activity, supporting high potential for phase III success and regulatory approval.
-
Pemvidutide’s dual mechanism targets both obesity and liver disease, positioning it as a differentiated MASH therapy. The phase II trial is robustly designed, with endpoints in weight loss, MASH resolution, and fibrosis improvement, and is supported by strong financials and strategic flexibility.
-
Pemvidutide, a dual GLP-1/glucagon agonist, is advancing in MASH, obesity, AUD, and ALD with unique trial designs and strong efficacy in weight loss and liver health. Key milestones include a 24-week IMPACT readout and phase III initiation in 2026.
-
Q1 2025 saw strengthened cash reserves, reduced net loss, and strategic financing to support pemvidutide's clinical development. IMPACT phase 2b MASH trial results are expected this quarter, with phase 2 trials in AUD and ALD set to begin soon.
-
Pemvidutide, a GLP-1/glucagon dual agonist, is advancing in a well-powered phase IIb trial for MASH, showing strong efficacy in liver fat reduction, weight loss, and safety. Top-line data are expected in Q2, with a solid cash position supporting further development and expansion into new liver indications.
-
Pemvidutide is advancing in obesity, MASH, AUD, and ALD, with strong phase II data and FDA-cleared INDs enabling direct phase II entry for new indications. The company is well-funded, aims for late-stage trials in 2025–2026, and plans to commercialize most indications independently.
-
Pemvidutide, a dual GLP-1/glucagon agonist, is advancing in both MASH and obesity with strong efficacy, safety, and tolerability. Phase II-B trials show class-leading liver fat reduction, weight loss, and lean mass preservation, with phase III programs and partnerships planned.
-
Pemvidutide, a GLP-1/glucagon dual agonist, showed strong weight loss, liver fat reduction, and lean mass preservation in Phase II studies. Upcoming MASH data may position it as a leading therapy for both fibrosis and weight loss, with further indications and pivotal trials planned.
Fiscal Year 2024
-
Significant progress in 2024 included completion of Phase 2b enrollment for pembedutide in MASH, FDA clearance for two new indications, and a strong cash position to fund operations into 2026. Top-line IMPACT trial data is expected in Q2 2025, with Phase 3 initiation planned for early 2026.
-
Key 2025 milestones include a phase 2b MASH readout and up to three new INDs, with a focus on leveraging glucagon's unique benefits for liver and lipid metabolism. The program is differentiated by strong weight loss effects, a favorable safety profile, and rapid regulatory progress.
-
Pemvidutide, a balanced GLP-1/glucagon dual agonist, is advancing in both obesity and MASH with strong safety and efficacy signals, including muscle preservation and lipid improvements. Phase 3 trials are underway, with key MASH data expected in Q2 next year.
-
Pemvidutide, a GLP-1/glucagon dual agonist, shows strong efficacy in weight loss, liver fat reduction, and lipid improvement, with a favorable safety profile and FDA support for pivotal trials. The company is advancing MASH independently, seeking a partner for obesity, and planning new indications.
-
Full enrollment of the phase 2b IMPACT trial in MASH and FDA alignment on a four-study phase 3 obesity program mark major milestones. Cash reserves of $139.4M fund operations into 2026, supporting new indications and ongoing partnership discussions.
-
Pemvidutide, a balanced GLP-1/glucagon dual agonist, shows strong efficacy in weight loss, lipid, and liver fat reduction, with a favorable safety profile. The phase III VELOCITY program and phase IIb MASH trial are advancing, with key data expected in 2Q25.
-
Pemvidutide, a dual GLP-1/glucagon agonist, shows rapid, robust effects on weight loss, liver fat, and lipids, with preserved lean mass. Phase IIb MASH trial readout is expected in Q2 next year, and commercialization could begin in 2028 for obesity and 2030 for MASH.
-
Pemvidutide showed strong weight loss and lean mass preservation in obesity trials, with significant lipid and liver fat reductions, supporting its differentiation in metabolic disease. Cash reserves fund operations into 2026, with key MASH data expected in Q1 2025.
-
Pemvidutide, a GLP-1/glucagon dual agonist, demonstrated strong weight loss, lipid, and liver fat reduction with best-in-class lean mass preservation and tolerability. Phase IIb MASH data is expected in Q1 next year, with strategic focus on regulatory engagement, partnerships, and market differentiation.
-
Pemvidutide, a GLP-1/glucagon dual agonist, is advancing toward phase III for obesity and NASH, with strong biomarker and clinical data supporting its differentiation and efficacy. Partnership discussions are ongoing, and pivotal NASH biopsy data are expected in Q1 next year.